Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| REGENERON PHARMACEUTICALS | 14 | 22 | -0,26 % | ||
| MEDPACE | 8 | - | +1,69 % | ||
| BIONTECH | 5 | 13 | 0,00 % | ||
| ALTIMMUNE | 5 | - | +2,43 % | ||
| HARMONY BIOSCIENCES | 2 | 17 | 0,00 % | ||
| BIOMARIN PHARMACEUTICAL | 2 | 12 | -0,78 % | ||
| TRAVERE THERAPEUTICS | 2 | 11 | +2,86 % | ||
| TERNS PHARMACEUTICALS | 2 | 2 | -0,77 % | ||
| TECTONIC THERAPEUTIC | 2 | 1 | 0,00 % | ||
| DEFINIUM THERAPEUTICS | 2 | - | -0,75 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:10 | Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML | 18 | GlobeNewswire (Europe) | - Regulatory Filing in Japan Planned Following Clinical Trial Completion -TOKYO and SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") and Kura Oncology,... ► Artikel lesen | |
| 14:06 | Humacyte, Inc: Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess | 3 | GlobeNewswire (USA) | ||
| 13:58 | Guggenheim hebt Kursziel für Travere Therapeutics nach FSGS-Zulassung an | 1 | Investing.com Deutsch | ||
| 13:58 | Schwächere Auftragslage: Mizuho senkt Kursziel für Medpace | 1 | Investing.com Deutsch | ||
| 13:54 | Guggenheim raises Travere Therapeutics stock price target on FSGS approval | 1 | Investing.com | ||
| 13:54 | Mizuho cuts Medpace stock price target on weaker bookings outlook | 1 | Investing.com | ||
| 13:42 | H.C. Wainwright reiterates Definium stock rating at buy on phase 3 progress | 2 | Investing.com | ||
| 13:42 | H.C. Wainwright reiterates Harmony Biosciences stock rating on IP litigation outlook | 1 | Investing.com | ||
| 13:34 | H.C. Wainwright bestätigt Kaufempfehlung für Harmony Biosciences angesichts des Patentstreits | 2 | Investing.com Deutsch | ||
| 13:12 | Regeneron Agrees To Lower Prescription Drug Prices Under MFN Deal | 239 | AFX News | WASHINGTON (dpa-AFX) - President Donald Trump has announced an MFN pricing deal with Regeneron to lower prescription drug prices that Americans pay for some of the world's most innovative drugs... ► Artikel lesen | |
| 13:06 | Sanofi's Cenrifki Gets Positive CHMP Nod For Secondary Progressive Multiple Sclerosis Treatment | 247 | AFX News | PARIS (dpa-AFX) - Sanofi SA (SNY) on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of Cenrifki for treating secondary progressive... ► Artikel lesen | |
| 13:06 | Merck clears antitrust hurdle for Terns acquisition | 2 | Investing.com | ||
| 12:58 | Merck: Kartellrechtliche Hürde für Terns-Übernahme genommen | 1 | Investing.com Deutsch | ||
| 12:54 | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET | 1 | GlobeNewswire (USA) | ||
| 12:46 | Regeneron cuts White House pricing deal, offers new gene therapy for free | 4 | Pharmaceutical Technology | ||
| 12:42 | Sanofi's tolebrutinib gets EU panel backing for MS treatment | 3 | Investing.com | ||
| 12:34 | EU-Ausschuss empfiehlt Zulassung für Sanofis MS-Medikament Tolebrutinib | 9 | Investing.com Deutsch | ||
| 12:34 | Sana Biotechnology strukturiert Direktorenklassen neu | 2 | Investing.com Deutsch | ||
| 12:30 | Biontech sendet Krisensignal: Was die wenigsten Anleger auf dem Schirm haben - Was ich konkret unternommen habe | Hebelschein-Spekulant | |||
| 12:27 | Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026) | 1 | The Motley Fool |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.